AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00884884
Drug: Aripiprazole 15, placebo
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg Aripiprazole daily plus placebo daily
Trial: NCT00884884
Drug: Aripiprazole 7.5, Placebo
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole 7.5 mg daily plus Placebo daily
Trial: NCT00884884
Drug: Topiramate 100, Placebo
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 100 mg daily plus Placebo daily
Trial: NCT00884884
Drug: Topiramate 200, Placebo
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 200 mg daily plus Placebo daily
Trial: NCT00884884
Drug: Topiramate 100, Aripiprazole 15
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 100 mg daily plus Aripiprazole 15mg daily
Trial: NCT00884884
Drug: Topiramate 100, Aripiprazole 7.5
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
Trial: NCT00884884
Drug: Topiramate 100, Aripiprazole 15mg
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 100 mg daily plus Aripiprazole 15mg daily
Trial: NCT00884884
Drug: Topiramate 200, Aripiprazole 7.5mg
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
Trial: NCT00884884
Drug: Topiramate 200, Aripiprazole 15
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 200mg daily plus Aripiprazole 15mg daily
Trial: NCT00642499
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg to 40 mg
Trial: NCT03377179
Drug: ABC294640
RxNorm normalized name: ABC294640
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 250 mg capsules of ABC294640 will be taken twice daily
Trial: NCT03377179
Drug: Hydroxychloroquine Sulfate 200 MG
RxNorm normalized name: hydroxychloroquine sulfate 200 MG
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCQ tablets will be taken at a dose that will be determined
Trial: NCT01138137
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles
Trial: NCT01138137
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg
Trial: NCT01138137
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles
Trial: NCT00509925
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
Trial: NCT00509925
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
Trial: NCT00242463
Drug: Nandrolone (anabolic steroid)
DrugBank: Nandrolone (DB13169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03866772
Drug: Misoprostol Oral Tablet
RxNorm normalized name: misoprostol Oral Tablet
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mcg oral consumption
Trial: NCT00497198
Drug: MCI-196
RxNorm normalized name: kaolin 196 MG/ML
DrugBank: Kaolin (DB01575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
Trial: NCT01075100
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 on Days 1 and 8
Trial: NCT01075100
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC=2.5 on Days 1 and 8
Trial: NCT01879085
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 IV given over 60 minutes on day 8 every 21 days (1 cycle)
Trial: NCT01879085
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, given over 67.5 minutes at 10 mg/m2/min
Trial: NCT01879085
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given orally at the specified dose levels (either 300 mg/daily or 200 mg twice per day) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle)
Trial: NCT01879085
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: administered on day 9 subcutaneously at 6 mg
Trial: NCT00788047
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan HCl 30 syrup single dose
Trial: NCT00788047
Drug: Dimebon + Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
Trial: NCT02270463
Drug: Tagraxofusp-erzs
RxNorm normalized name: tagraxofusp-erzs
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tagraxofusp-Erzs administered by IV infusion at doses of 7, 9, and 12 µg/kg/day
Trial: NCT01239537
Drug: Seasonal Flu vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of seasonal trivalent flu vaccine (Fluarix)
Trial: NCT00874484
Drug: Clexane (enoxaparin)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One arm receives enoxoparin, second arm receives saline
Trial: NCT02813447
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00747721
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
Trial: NCT01612221
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
Trial: NCT03386305
Drug: EnvarsusXR
RxNorm normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to study drug will be converted to EnvarsusXR once daily.
Trial: NCT03386305
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients continue to take Tacrolimus BID, as a part of routine care.
Trial: NCT00710814
Drug: Leptin
RxNorm normalized name: Leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
Trial: NCT00742014
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
Trial: NCT02642263
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum uterotonic drug
Trial: NCT00770640
Drug: Pioglitazone and insulin
RxNorm normalized name: glimepiride and pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
Trial: NCT00770640
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
Trial: NCT00003212
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02618564
Drug: Sennosides
RxNorm normalized name: Sennosides
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each group will be assigned different doses of sennosides and varying times of administration
Trial: NCT00088452
Drug: Ethosuximide
RxNorm normalized name: Ethosuximide
DrugBank: Ethosuximide (DB00593)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethosuximide is a common treatment for childhood absence epilepsy.
Trial: NCT00088452
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine is a common treatment for childhood absence epilepsy.
Trial: NCT00088452
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid is a common treatment for childhood absence epilepsy.
Trial: NCT02629419
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lipid nanocrystal formulation of amphotericin B
Trial: NCT00541840
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity.
Trial: NCT00178256
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
Trial: NCT02453087
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.
Trial: NCT02453087
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
Trial: NCT00018161
Drug: Mecamylamine
RxNorm normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00018161
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02771210
Drug: Secukinumab Placebo
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
Trial: NCT00872469
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2 grams by intravenous injection
Trial: NCT03354897
Drug: Torasemide 5Mg Tablet
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 weeks treatment
Trial: NCT02208882
Drug: BMS-986120
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02208882
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03821415
Drug: RP101
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 17β-oestradiol-3-phosphate ophthalmic sterile solution
Trial: NCT00634322
Drug: glucarpidase
RxNorm normalized name: Glucarpidase
DrugBank: Glucarpidase (DB08898)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV dose based on weight, two doses given for 5 minutes, 24 hours apart
Trial: NCT03249402
Drug: JNJ-42847922
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21 in cycle 2.
Trial: NCT03862651
Drug: Cangrelor
RxNorm normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
Trial: NCT00654329
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline, given intranasally
Trial: NCT00654329
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine, transmucosal, 1 microgram/kilogram
Trial: NCT00654329
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine, 2 microgram/kilogram, transmucosal route
Trial: NCT01426906
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
Trial: NCT01426906
Drug: rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
Trial: NCT04059913
Drug: Roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Trial: NCT00814632
Drug: CC-10004
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-10004 20 mg. twice a day for 12 weeks
Trial: NCT01319864
Drug: Plerixafor Dose Escalation
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy.
Trial: NCT02004132
Drug: Axiron
RxNorm normalized name: Axiron
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution administered topically using pump and applicator
Trial: NCT04488978
Drug: Irbesartan/Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QID
Trial: NCT01319825
Drug: milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
Trial: NCT00392704
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy
Trial: NCT00392704
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy
Trial: NCT00392704
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy
Trial: NCT00392704
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
Trial: NCT00531063
Drug: Everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00508859
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maintenance treatment with sertraline
Trial: NCT02459236
Drug: CERC-301
RxNorm normalized name: CERC-301
DrugBank: CERC-301 (DB12063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
Trial: NCT03749148
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-IL4-Receptor alpha
Trial: NCT00046683
Drug: alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004097
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004097
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01878136
Drug: Tissue Plasminogen Activator
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
Trial: NCT00349245
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04514796
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SB5 (adalimumab), 40 mg, single-dose
Trial: NCT00001160
Drug: 68-Gallium Dotatate
RxNorm normalized name: Gallium 68 dotatate
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For evaluation risk/benefit evaluation
Trial: NCT02136342
Drug: chlorogenic acid
RxNorm normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00873561
Drug: NBI-6024
RxNorm normalized name: NBI-6024
DrugBank: NBI-6024 (DB05819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
Trial: NCT01631617
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800/160 orally every 12 hours for 14 days
Trial: NCT01631617
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg orally every 8 hours for 14 days
Trial: NCT04235270
Drug: Macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 10 mg tablet will be administered orally as free combination.